---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-146134"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:48:55.920910+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kymera and Gilead sign option/license deal for CDK2 degraders; up to $750M

## Summary
- Up to $750M total payments including $85M upfront/option exercise payments.
- Tiered royalties ranging from high-single-digit to mid-teens on net sales.
- Kymera leads all research; Gilead obtains global development/manufacturing/commercialization rights.
- CDK2 degraders target breast cancer and other solid tumors.
- Agreement announced June 25, 2025.

## SEC filing metadata
- accession: 0001193125-25-146134
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525146134/0001193125-25-146134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525146134/d923971d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-146134
- JSON: https://secwatch.observer/filing/0001193125-25-146134.json
- Plain text: https://secwatch.observer/filing/0001193125-25-146134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.